Explaining the Medicare Drug-Plan Subsidy That Trump Is Ending
FactCheck.org — 2026-08-10 13:13:00 — www.factcheck.org
Trump Administration Ends Medicare Part D Premium Subsidy, Raising Concerns Over Higher Costs for Seniors
The Trump administration has announced it will end a temporary subsidy that has been reducing premiums for Medicare Part D standalone prescription drug plans—a move that could lead to higher costs for some Medicare beneficiaries.
Subsidy Program to End in 2027
The subsidy, originally put in place by the Biden administration and intended to run through at least 2027, was designed to offset expected premium increases after significant changes to the Part D benefit. The Trump administration renewed the subsidy at a lower level for 2026, but has now decided it will not continue in 2027.
Potential Impact on Seniors
Analysts warn that the end of this subsidy could result in higher prescription drug premiums for some Medicare recipients. The full impact will not be clear until the federal government releases detailed information about 2027 premiums this fall. The temporary subsidy had been effective in reducing premiums by an estimated $16 per month on average for 2026, according to the federal Medicare Payment Advisory Commission. Without it, some seniors might face nearly 50% higher costs for drug coverage.
Administration’s Position
Officials from the Centers for Medicare & Medicaid Services, under the Trump administration, argue that the market has stabilized and the subsidy is no longer necessary. They claim that most Medicare recipients will see premiums rise by less than $10 per month, with many even seeing lower premiums. However, outside experts caution that without the enhanced financial support, some beneficiaries could face deeper premium increases, and there may be changes in drug coverage or cost-sharing as insurers adjust.
Broader Implications
The move could also affect the stability of the standalone Part D market, especially in rural areas where Medicare Advantage options are limited. Experts note that standalone Part D plans already face stronger financial challenges compared to Medicare Advantage plans, which are more heavily subsidized.
Conclusion
While the Trump administration maintains that ending the subsidy will not lead to significant premium increases for most, experts and advocates urge Medicare beneficiaries to review their options carefully during open enrollment this fall. The ultimate impact on premiums and coverage will become clearer when new plan details are released in September.
Source: https://www.factcheck.org/2026/08/explaining-the-medicare-drug-plan-subsidy-that-trump-is-ending/